Key Points
- Insider sale: Director Brian Daniel Webster sold 15,000 shares on March 17 at an average price of $20.27 for $304,050, cutting his stake to 364,786 shares (a ~3.95% ownership decrease) — his fourth consecutive 15,000-share sale since December (60,000 shares total).
- Quarterly results: Kestra reported a loss of ($0.61) EPS (miss by $0.01) and revenue of $24.55 million (up 62.7% YoY), while still showing a deeply negative net margin (171.87%) and return on equity (-65.49%).
- Analyst and market view: The stock has a consensus "Moderate Buy" (6 Buys, 1 Hold, 1 Sell) with a $29 average target, a $1.14 billion market cap, and a 52-week range of $13.25–$30.00.
Kestra Medical Technologies, Ltd. (NASDAQ:KMTS - Get Free Report) insider Brian Daniel Webster sold 15,000 shares of the business's stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $20.27, for a total transaction of $304,050.00. Following the completion of the sale, the insider directly owned 364,786 shares in the company, valued at $7,394,212.22. This represents a 3.95% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Brian Daniel Webster also recently made the following trade(s):
- On Tuesday, February 17th, Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $25.60, for a total value of $384,000.00.
- On Thursday, January 15th, Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $22.80, for a total value of $342,000.00.
- On Monday, December 29th, Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $26.59, for a total value of $398,850.00.
Kestra Medical Technologies Stock Down 0.1%
KMTS stock opened at $19.56 on Friday. The company has a debt-to-equity ratio of 0.15, a current ratio of 7.32 and a quick ratio of 5.47. The stock has a market capitalization of $1.14 billion and a P/E ratio of -4.94. Kestra Medical Technologies, Ltd. has a fifty-two week low of $13.25 and a fifty-two week high of $30.00. The business has a 50-day moving average of $24.05 and a 200-day moving average of $24.50.
Kestra Medical Technologies (NASDAQ:KMTS - Get Free Report) last announced its earnings results on Tuesday, March 17th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.01). The firm had revenue of $24.55 million during the quarter. Kestra Medical Technologies had a negative net margin of 171.87% and a negative return on equity of 65.49%. The company's revenue for the quarter was up 62.7% on a year-over-year basis.
Hedge Funds Weigh In On Kestra Medical Technologies
A number of institutional investors have recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD raised its position in Kestra Medical Technologies by 137.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,369,429 shares of the company's stock worth $115,878,000 after acquiring an additional 2,529,851 shares in the last quarter. Eventide Asset Management LLC grew its position in shares of Kestra Medical Technologies by 285.7% in the 2nd quarter. Eventide Asset Management LLC now owns 1,060,557 shares of the company's stock valued at $17,584,000 after acquiring an additional 785,557 shares during the period. Franklin Resources Inc. increased its stake in shares of Kestra Medical Technologies by 180.8% during the 4th quarter. Franklin Resources Inc. now owns 951,008 shares of the company's stock worth $25,221,000 after purchasing an additional 612,343 shares during the last quarter. Millennium Management LLC bought a new stake in shares of Kestra Medical Technologies in the 1st quarter valued at about $11,036,000. Finally, Brown Advisory Inc. lifted its stake in Kestra Medical Technologies by 34.1% in the 4th quarter. Brown Advisory Inc. now owns 1,688,356 shares of the company's stock valued at $44,775,000 after purchasing an additional 428,996 shares during the last quarter.
Analyst Upgrades and Downgrades
KMTS has been the topic of a number of research reports. Wells Fargo & Company boosted their price objective on shares of Kestra Medical Technologies from $27.00 to $28.00 and gave the stock an "overweight" rating in a research report on Friday, December 12th. Piper Sandler raised their target price on shares of Kestra Medical Technologies from $27.00 to $30.00 and gave the company an "overweight" rating in a research report on Friday, December 12th. Stifel Nicolaus set a $30.00 price target on shares of Kestra Medical Technologies in a research report on Friday, December 12th. Weiss Ratings restated a "sell (d-)" rating on shares of Kestra Medical Technologies in a research note on Wednesday, December 24th. Finally, BTIG Research restated a "buy" rating and issued a $32.00 price objective on shares of Kestra Medical Technologies in a report on Wednesday. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Kestra Medical Technologies has a consensus rating of "Moderate Buy" and a consensus price target of $29.00.
Check Out Our Latest Research Report on KMTS
About Kestra Medical Technologies
(
Get Free Report)
We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
